MBX BiosciencesMBX
Recorded

MBX Biosciences Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezSenior Biopharma Analyst

All right. Well, welcome everybody, and thanks for joining us here at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggenheim, and I'm really pleased to be joined again this year by MBX Biosciences. To my immediate left is CEO Steve Hoerter. To his left is Sam Azoulay, Chief Medical Officer, and to Sam's left is John Smither, CFO. Maybe just to level set the playing field, thanks for joining us, of course, but Steve, you stepped into this CEO role in July after serving as executive chairman. Maybe just talk about where MBX is today, your top priorities for the company, and the next phase as both a late-stage rare endocrine drug company, but also a company with potential best-in-class long-acting obesity assets in the portfolio.

Steve HoerterCEO

Yeah. Thanks, Seamus, and thanks for the invitation to join the conference this year. It's always a great conference, and Sam and John and I and the rest of the team are really delighted to be here. It's been a transformational year for MBX. If you think back to the summertime, we had the one-year, the 12-month open-label extension data for canvuparatide from the phase II AVAIL study demonstrating sustained clinical benefit for Canvu in patients with chronic hypoparathyroidism. Now, as we are in Q4, we started the phase III study of canvuparatide in chronic HP. We're really excited about physician receptivity to that study and patient enthusiasm, and we're on our way to the potential to become a commercial-stage company. So we're really excited on the Canvu front of where we are with this potential best-in-class therapy for patients.

Steve HoerterCEO

Earlier in the summer, back in May, as you'll remember, we reported early blinded data from the phase I study of MBX 4291, and this is our long-acting co-agonist, GLP-1/GIP co-agonist for the treatment of obesity. Again, leveraging the platform technology that we've built that's part of MBX, the same prodrug technology that we use in canvuparatide, for example. In those early data, we were really excited about what we saw, even though blinded data, relatively small n. So now, as we fast-forward, we'll talk about the balance of the year here in a second, but we're excited about the progress we're making with 4291 and the potential for that to really be fundamentally game-changing in the field of obesity.

Steve HoerterCEO

I think in terms of the priorities that we have for this year, it's really about continuing to execute on enrollment in the phase III canvuparatide study in HP while we also advance the rest of the obesity portfolio, including 4291.

Seamus FernandezSenior Biopharma Analyst

Great. At your Obesity Day, you shared this initial blinded phase I data for 4291. Maybe just the key takeaways that you would encourage folks to really key into that informed views on weight loss and tolerability and what you really kind of see as the target product profile for that asset.

Sam AzoulayChief Medical Officer

Yeah. Thank you, Seamus. Let's start with just a reminder about the dose, that was the dose titration, right? It was an eight-week period during which patients were exposed to 30 milligram weekly for four weeks, followed by 120 milligram. I'm going to start with the PK, which is probably the most important learning because it's directly related to the platform, the PEP platform. If you look at the curve, the concentration of the active MBX 4291, you have a slow raise, smooth raise to the Cmax, right? We know that this raise, most of the case, with other product create a burst, and the burst is related to the GI intolerability. Here, it's a smooth. Then the concentration is sustained, and with the time to halve the Cmax of 26 days as compared to MOUNJARO, which was 21 days.

Sam AzoulayChief Medical Officer

Here, you have a really already a confirmation for the monthly administration, right? Now looking at the weight loss, it was blinded, still blinded, and we had 7% weight loss at eight weeks. Again, with a range from 0% to 16%. If you look at the tolerability, again, excellent tolerability profile with this limited number of subject, but nevertheless, we had only one episode of diarrhea. Back to the PK curve, how to explain this good tolerability also is the way, the raise to the Cmax, right? The sustainability with the lack of fluctuation, and that explain why we got this tolerability. Good learning from this initial dose regimen.

Seamus FernandezSenior Biopharma Analyst

Perfect. Steve, maybe you can talk about the upcoming data, and what you see as kind of the target product profile. Maybe following on to that, Sam, do you believe cohort one is sufficient to kind of predict an ability to move forward with confidence into phase II?

Steve HoerterCEO

Yeah, so the milestone coming up for 4291 is, you're exactly right, is the unblinding of the study, and specifically with a focus on cohort C1. Sam just described the dose and schedule from B1 that we had as blinded data at the Obesity Day event back in May. The dose and schedule for this cohort C1 is 30 milligrams once weekly times four, followed by a monthly dose of 120, followed by another monthly dose of 180 milligrams. The TPP that we're trying to achieve is competitive weight lowering, and when you look into the landscape at whether it's tirzepatide or sema or BARO from Pfizer, what you see is a 6%-8% weight loss at that 12-week time point. So we aim to be competitive with that.

Steve HoerterCEO

The second part of the TPP is around having a true once monthly, and we think this is now fundamentally differentiating, even based on the data we showed, the PK data we showed back in May. There just are no other coagonists or monoagonists that offer true once-monthly dosing. So that's the second pillar of the TPP. Then the third, as Sam described, based on the PK profile and this slow rise to Cmax, is to differentiate based on tolerability. We can talk about relevant measures of that, Seamus. Vomiting is probably the easiest one. So GI intolerance generally, but vomiting specifically. When you look at tirzepatide data, phase III data, what you see, depending on dose and depending on study, is a range of anywhere from 8% rate of vomiting with low-dose tirzepatide up to 18% rate of vomiting.

Steve HoerterCEO

So we think we have the potential to improve upon that based on the differentiated PK profile.

Seamus FernandezSenior Biopharma Analyst

Great. Sam, just following on to what this is going to help predict, is do you need C1 to be able to advance as well, or is B1, from your perspective, enough to really predict an ability to move forward into phase II?

Sam AzoulayChief Medical Officer

I mean, C1 is a continuum of B1, right?

Sam AzoulayChief Medical Officer

Yeah. It's a longer period with an additional monthly dose of 180 milligram, larger population exposed to the drug, so learning will be coming from C1.

Sam AzoulayChief Medical Officer

When you want to move a program forward, you look at the totality of evidence.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day